TSPAN2 Is Involved in Cell Invasion and Motility during Lung Cancer Progression

Cell Reports

Volumn 7, Issue 2, 2014, Pages 527-538

  Otsubo, Chihiro ^a,b,d   Otomo, Ryo ^a,b   Miyazaki, Makoto ^a,b   Matsushima Hibiya, Yuko ^a   Kohno, Takashi ^a   Iwakawa, Reika ^a   Takeshita, Fumitaka ^a   Okayama, Hirokazu ^a,e   Ichikawa, Hitoshi ^a   Saya, Hideyuki ^c   Kiyono, Tohru ^a   Ochiya, Takahiro ^a   Tashiro, Fumio ^b   Nakagama, Hitoshi ^a   Yokota, Jun ^a   Enari, Masato ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b TOKYO UNIVERSITY OF SCIENCE   (Japan)

^c KEIO UNIVERSITY   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN; K RAS PROTEIN; MEMBRANE PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; TSPAN2 PROTEIN; UNCLASSIFIED DRUG; CD44 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; NERVE PROTEIN; ONCOPROTEIN; RAS PROTEIN; TETRASPANIN; TSPAN2 PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER GROWTH; CANCER PROGNOSIS; CELL MOTILITY; CELL SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; GENE ACTIVATION; GENE EXPRESSION; GENE INACTIVATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LIVER METASTASIS; LUNG ADENOCARCINOMA; LUNG CARCINOGENESIS; LUNG METASTASIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR INVASION; ANIMAL; CELL CULTURE; CELL MOTION; EPITHELIUM CELL; GENETICS; LUNG TUMOR; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD44; CELL LINE, TUMOR; CELL MOVEMENT; CELLS, CULTURED; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; HUMANS; LUNG NEOPLASMS; MICE, NUDE; MUTATION; NEOPLASM INVASIVENESS; NERVE TISSUE PROTEINS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; TETRASPANINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84899627865     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.03.027     Document Type: Article

References (58)

1. Amson R., Pece S., Lespagnol A., Vyas R., Mazzarol G., Tosoni D., Colaluca I., Viale G., Rodrigues-Ferreira S., Wynendaele J., et al. Reciprocal repression between P53 and TCTP. Nat. Med. 2012, 18:91-99.
2. André M., Le Caer J.P., Greco C., Planchon S., El Nemer W., Boucheix C., Rubinstein E., Chamot-Rooke J., Le Naour F. Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics 2006, 6:1437-1449.
3. Armengaud J., Jouanneau Y. Addition of a class IIS enzyme site in the mutagenic primer to improve two-step PCR-based targeted mutagenesis. Nucleic Acids Res. 1993, 21:4424-4425.
4. Aylon Y., Oren M. New plays in the p53 theater. Curr. Opin. Genet. Dev. 2011, 21:86-92.
5. Biddle A., Mackenzie I.C. Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev. 2012, 31:285-293.
6. Böhlig L., Rother K. One function-multiple mechanisms: the manifold activities of p53 as a transcriptional repressor. J.Biomed. Biotechnol. 2011, 2011:464916.
7. Bourdon J.C., Laurenzi V.D., Melino G., Lane D. p53: 25 years of research and more questions to answer. Cell Death Differ. 2003, 10:397-399.
8. Deonarain M.P., Kousparou C.A., Epenetos A.A. Antibodies targeting cancer stem cells: a new paradigm in immunotherapy?. MAbs 2009, 1:12-25.
9. Ding L., Getz G., Wheeler D.A., Mardis E.R., McLellan M.D., Cibulskis K., Sougnez C., Greulich H., Muzny D.M., Morgan M.B., et al. Somatic mutations affect key pathways in lung adenocarcinoma. Nature 2008, 455:1069-1075.
10. Dua P., Kim S., Lee D.K. Nucleic acid aptamers targeting cell-surface proteins. Methods 2011, 54:215-225.
11. Enari M., Ohmori K., Kitabayashi I., Taya Y. Requirement of clathrin heavy chain for p53-mediated transcription. Genes Dev. 2006, 20:1087-1099.
12. Forgacs E., Zöchbauer-Müller S., Oláh E., Minna J.D. Molecular genetic abnormalities in the pathogenesis of human lung cancer. Pathol. Oncol. Res. 2001, 7:6-13.
13. Gadea G., de Toledo M., Anguille C., Roux P. Loss of p53 promotes RhoA-ROCK-dependent cell migration and invasion in 3D matrices. J.Cell Biol. 2007, 178:23-30.
14. Geiger T.R., Peeper D.S. Metastasis mechanisms. Biochim. Biophys. Acta 2009, 1796:293-308.
15. Godar S., Ince T.A., Bell G.W., Feldser D., Donaher J.L., Bergh J., Liu A., Miu K., Watnick R.S., Reinhardt F., et al. Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression. Cell 2008, 134:62-73.
16. Haeuw J.F., Goetsch L., Bailly C., Corvaia N. Tetraspanin CD151 as a target for antibody-based cancer immunotherapy. Biochem. Soc. Trans. 2011, 39:553-558.
17. Hemler M.E. Targeting of tetraspanin proteins-potential benefits and strategies. Nat. Rev. Drug Discov. 2008, 7:747-758.
18. Ishimoto T.N., Nagano O., Yae T., Tamada M., Motohara T., Oshima H., Oshima M., Ikeda T., Asaba R., Yagi H., et al. CD44 variant regulates redox status in cancer cells by stabilizing the xCT subunit of system xc(-) and thereby promotes tumor growth. Cancer Cell 2011, 19:387-400.
19. Iwakawa R., Kohno T., Anami Y., Noguchi M., Suzuki K., Matsuno Y., Mishima K., Nishikawa R., Tashiro F., Yokota J. Association of p16homozygous deletions with clinicopathologic characteristics and EGFR/KRAS/p53 mutations in lung adenocarcinoma. Clin. Cancer Res. 2008, 14:3746-3753.
20. Iwakawa R., Kohno T., Enari M., Kiyono T., Yokota J. Prevalence of human papillomavirus 16/18/33 infection and p53 mutation in lung adenocarcinoma. Cancer Sci. 2010, 101:1891-1896.
21. Johnson R.A., Ince T.A., Scotto K.W. Transcriptional repression by p53 through direct binding to a novel DNA element. J.Biol. Chem. 2001, 276:27716-27720.
22. Kim E.K., Choi E.J. Pathological roles of MAPK signaling pathways in human diseases. Biochim. Biophys. Acta 2010, 1802:396-405.
23. Kim N.H., Kim H.S., Li X.Y., Lee I., Choi H.S., Kang S.E., Cha S.Y., Ryu J.K., Yoon D., Fearon E.R., et al. A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial-mesenchymal transition. J.Cell Biol. 2011, 195:417-433.
24. Kitamura H., Okudela K. Bronchioloalveolar neoplasia. Int J Clin Exp Pathol 2010, 4:97-99.
25. Ko Y.H., Won H.S., Jeon E.K., Hong S.H., Roh S.Y., Hong Y.S., Byun J.H., Jung C.K., Kang J.H. Prognostic significance of CD44s expression in resected non-small cell lung cancer. BMC Cancer 2011, 11:340.
26. Kobayashi C.I., Suda T. Regulation of reactive oxygen species in stem cells and cancer stem cells. J.Cell. Physiol. 2012, 227:421-430.
27. Kogan-Sakin I., Tabach Y., Buganim Y., Molchadsky A., Solomon H., Madar S., Kamer I., Stambolsky P., Shelly A., Goldfinger N., et al. Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2011, 18:271-281.
28. Lane D., Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2010, 2:a000893.
29. Le Naour F., André M., Greco C., Billard M., Sordat B., Emile J.F., Lanza F., Boucheix C., Rubinstein E. Profiling of the tetraspanin web of human colon cancer cells. Mol. Cell. Proteomics 2006, 5:845-857.
30. Li M., He Y., Dubois W., Wu X., Shi J., Huang J. Distinct regulatory mechanisms and functions for p53-activated and p53-repressed DNA damage response genes in embryonic stem cells. Mol. Cell 2012, 46:30-42.
31. Liu B., Chen Y., St Clair D.K. ROS and p53: a versatile partnership. Free Radic. Biol. Med. 2008, 44:1529-1535.
32. Lundin A., Driscoll B. Lung cancer stem cells: progress and prospects. Cancer Lett. 2013, 338:89-93.
33. Majidi M., Al-Wadei H.A., Takahashi T., Schuller H.M. Nongenomic beta estrogen receptors enhance beta1 adrenergic signaling induced by the nicotine-derived carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human small airway epithelial cells. Cancer Res. 2007, 67:6863-6871.
34. Malemud C.J. Inhibitors of stress-activated protein/mitogen-activated protein kinase pathways. Curr. Opin. Pharmacol. 2007, 7:339-343.
35. Mizuno H., Kitada K., Nakai K., Sarai A. PrognoScan: a new database for meta-analysis of the prognostic value of genes. BMC Med. Genomics 2009, 2:18.
36. Muller P.A., Caswell P.T., Doyle B., Iwanicki M.P., Tan E.H., Karim S., Lukashchuk N., Gillespie D.A., Ludwig R.L., Gosselin P., et al. Mutant p53 drives invasion by promoting integrin recycling. Cell 2009, 139:1327-1341.
37. Muller P.A., Vousden K.H., Norman J.C. p53 and its mutants in tumor cell migration and invasion. J.Cell Biol. 2011, 192:209-218.
38. Murayama Y.S., Shinomura Y., Oritani K., Miyagawa J., Yoshida H., Nishida M., Katsube F., Shiraga M., Miyazaki T., Nakamoto T., et al. The tetraspanin CD9 modulates epidermal growth factor receptor signaling in cancer cells. J.Cell. Physiol. 2008, 216:135-143.
39. Nakamura M., Suemizu H. Novel metastasis models of human cancer in NOG mice. Curr. Top. Microbiol. Immunol. 2008, 324:167-177.
40. Nakamura H., Suenaga N., Taniwaki K., Matsuki H., Yonezawa K., Fujii M., Okada Y., Seiki M. Constitutive and induced CD44 shedding by ADAM-like proteases and membrane-type 1 matrix metalloproteinase. Cancer Res. 2004, 64:876-882.
41. Ohata H., Miyazaki M., Otomo R., Matsushima-Hibiya Y., Otsubo C., Nagase T., Arakawa H., Yokota J., Nakagama H., Taya Y., Enari M. NuMA is required for the selective induction of p53 target genes. Mol. Cell. Biol. 2013, 33:2447-2457.
42. Oren M. Decision making by p53: life, death and cancer. Cell Death Differ. 2003, 10:431-442.
43. Rayess H., Wang M.B., Srivatsan E.S. Cellular senescence and tumor suppressor gene p16. Int. J. Cancer 2012, 130:1715-1725.
44. Robles A.I., Harris C.C. Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb. Perspect. Biol. 2010, 2:a001016.
45. Romanska H.M., Berditchevski F. Tetraspanins in human epithelial malignancies. J.Pathol. 2011, 223:4-14.
46. Sadej R., Romanska H., Kavanagh D., Baldwin G., Takahashi T., Kalia N., Berditchevski F. Tetraspanin CD151 regulates transforming growth factor beta signaling: implication in tumor metastasis. Cancer Res. 2010, 70:6059-6070.
47. Sato M., Vaughan M.B., Girard L., Peyton M., Lee W., Shames D.S., Ramirez R.D., Sunaga N., Gazdar A.F., Shay J.W., Minna J.D. Multiple oncogenic changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) are not sufficient to confer a full malignant phenotype on human bronchial epithelial cells. Cancer Res. 2006, 66:2116-2128.
48. Shedden K., Taylor J.M., Enkemann S.A., Tsao M.S., Yeatman T.J., Gerald W.L., Eschrich S., Jurisica I., Giordano T.J., Misek D.E., et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat. Med. 2008, 14:822-827. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma.
49. Stamenkovic I., Yu Q. Shedding light on proteolytic cleavage ofCD44: the responsible sheddase and functional significance of shedding. J.Invest. Dermatol. 2009, 129:1321-1324.
50. Tiemann F., Zerrahn J., Deppert W. Cooperation of simian virus 40 large and small T antigens in metabolic stabilization of tumor suppressor p53 during cellular transformation. J.Virol. 1995, 69:6115-6121.
51. Tsai Y.C., Weissman A.M. Dissecting the diverse functions of the metastasis suppressor CD82/KAI1. FEBS Lett. 2011, 585:3166-3173.
52. Vinot S., Anguille C., de Toledo M., Gadea G., Roux P. Analysis of cell migration and its regulation by Rho GTPases and p53 in a three-dimensional environment. Methods Enzymol. 2008, 439:413-424.
53. Wang H.X., Li Q., Sharma C., Knoblich K., Hemler M.E. Tetraspanin protein contributions to cancer. Biochem. Soc. Trans. 2011, 39:547-552.
54. Xu D., Sharma C., Hemler M.E. Tetraspanin12 regulates ADAM10-dependent cleavage of amyloid precursor protein. FASEB J. 2009, 23:3674-3681.
55. Yilmaz M., Christofori G. EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev. 2009, 28:15-33.
56. Zhang Z., Leonard S.S., Huang C., Vallyathan V., Castranova V., Shi X. Role of reactive oxygen species and MAPKs in vanadate-induced G(2)/M phase arrest. Free Radic. Biol. Med. 2003, 34:1333-1342.
57. Zhao H., Tanaka T., Mitlitski V., Heeter J., Balazs E.A., Darzynkiewicz Z. Protective effect of hyaluronate on oxidative DNA damage in WI-38 and A549 cells. Int. J. Oncol. 2008, 32:1159-1167.
58. Zuckerman V., Wolyniec K., Sionov R.V., Haupt S., Haupt Y. Tumour suppression by p53: the importance of apoptosis and cellular senescence. J.Pathol. 2009, 219:3-15.